JPRN-UMIN000005936
Recruiting
Phase 2
Phase II study of allogeneic hematopoietic stem cell transplantation using a preparative regimens consisting of iv Bu + Flu + L-PAM for patients with juvenile myelomonocytic leukemia (JMML) - JMML-11
Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)0 sites43 target enrollmentJuly 7, 2011
ConditionsJuvenile myelomonocytic leukemia (JMML)
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Juvenile myelomonocytic leukemia (JMML)
- Sponsor
- Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)
- Enrollment
- 43
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Diagnosis of Noonan syndrome, disorders with germline RAS mutations and ALPS\-like diseases with somatic RAS mutations. Intracranial hemorrhage. Heart failure requiring treatment. Chronic renal failure. Active uncontrolled infections. Uncontrolled diabetes mellitus. Liver cirrhosis. Psychiatric problems.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase II study of allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies using once daily intravenous busulfan and fludarabine as conditioning regimeacute myeloid leukemia(AML) myelodysplastic syndrome(MDS) chronic myelogenous leukemia(CML)JPRN-UMIN000009766Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital75
Completed
Phase 2
A phase II study of allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies using intravenous busulfan and cyclophosphamide as conditioning regimen.CML(chronic myelogenous leukemia) AML(acute myeloid leukemia) MDS(myelodysplastic syndrome)JPRN-UMIN000003648Kanto Study Group for Cell Therapy Nagoya Blood and Marrow Transplantation (NBMT) Group40
Recruiting
Phase 2
AML-SCT15acute myeloid leukemia (AML)JPRN-jRCTs051180190YABE Hiromasa66
Recruiting
Phase 2
Phase II study of allogeneic hematopoietic cell transplantation for children with acute myeloid leukemia in first and second complete remission using fludarabine, cytarabine, melphalan and low-dose total body irradiation as a conditioning regimen (AML-SCT15).acute myeloid leukemia (AML)JPRN-UMIN000027821Japan Children's Cancer Group (JCCG)66
Recruiting
Not Applicable
Clinical Phase II Study of hematopoietic stem ctell transplantation for ataxia telangiectasia and related diseasesataxia telangiectasia DNA damage response disorderJPRN-UMIN000019532Graduate Schoool, Dept. of Community Pediatrics, Perinatal and Maternal Medicine, Tokyo Medical and Dental University5